HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

Abstract
A novel bispecific antibody-derived recombinant protein targeting leukemias and lymphomas was designed, a single-chain Fv triple body (sctb) consisting of 1 polypeptide chain with 3 scFvs connected in tandem. The distal scFvs were specific for the tumor antigen CD19, and the central scFv for the trigger molecule CD16 (FcgammaRIII) on natural killer (NK) cells and macrophages. We had previously built a disulphide stabilized (ds) bsscFv [19 x 16] with monovalent binding for CD19 from ds components. The sctb ds[19 x 16 x 19] also used ds components and displayed 3-fold greater avidity for CD19 than the bsscFv (KD = 13 vs. 42 nM), whereas both had equal affinity for CD16 (KD = 58 nM). Plasma half-lives in mice were 4 and 2 hours for the sctb and the bsscFv, respectively. In antibody-dependent cellular cytotoxicity reactions with human mononuclear cells as effectors, the sctb promoted equal lysis of leukemic cell lines and primary cells from leukemia and lymphoma patients at 10-fold to 40-fold lower concentrations than the bsscFv. This new format may also be applicable to a variety of other tumor antigens and effector molecules. With half-maximum effective concentrations (EC50) in the low picomolar range, the sctb ds[19 x 16 x 19] is an attractive candidate for further preclinical evaluation.
AuthorsChristian Kellner, Joerg Bruenke, Julia Stieglmaier, Michael Schwemmlein, Michael Schwenkert, Heiko Singer, Kristin Mentz, Matthias Peipp, Peter Lang, Fuat Oduncu, Bernhard Stockmeyer, Georg H Fey
JournalJournal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) 2008 Nov-Dec Vol. 31 Issue 9 Pg. 871-84 ISSN: 1537-4513 [Electronic] United States
PMID18833000 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bispecific
  • Antigens, CD19
  • Immunoglobulin Fragments
  • Receptors, IgG
  • Recombinant Fusion Proteins
Topics
  • Animals
  • Antibodies, Bispecific (chemistry, genetics, immunology, therapeutic use)
  • Antibody-Dependent Cell Cytotoxicity
  • Antigens, CD19 (genetics, immunology, metabolism)
  • CHO Cells
  • Cloning, Molecular
  • Cricetinae
  • Cricetulus
  • Humans
  • Immunoglobulin Fragments (chemistry, genetics, immunology, metabolism, therapeutic use)
  • Immunotherapy
  • Killer Cells, Natural (immunology, metabolism, pathology)
  • Leukemia (immunology, pathology, therapy)
  • Macrophages (immunology, metabolism, pathology)
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Receptors, IgG (genetics, immunology, metabolism)
  • Recombinant Fusion Proteins (chemistry, immunology, metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: